Article
Oncology
Maiyue He, Jiaxuan Liu, Zijing Wang, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Peng Yuan, Yang Luo, Ying Fan, Hongnan Mo, Bo Lan, Qiao Li, Binghe Xu
Summary: The combination of orally administered metronomic capecitabine and pyrotinib in HER2 positive metastatic breast cancer patients shows promising efficacy and improved tolerability.
Review
Medicine, General & Internal
Marina Elena Cazzaniga, Serena Capici, Nicoletta Cordani, Viola Cogliati, Francesca Fulvia Pepe, Francesca Riva, Maria Grazia Cerrito
Summary: This review summarizes the advantages and challenges of metronomic chemotherapy (mCHT) in preclinical and clinical settings. In preclinical studies, mCHT has a significant effect on the tumor microenvironment, but the direct effects on tumor cells are less clear. Key issues that need to be addressed include the lack of definition of an optimal biological dose, administration method, and validation of predictive biomarkers. In the clinical context, low toxicity is the most recognized advantage of mCHT, but the type of study design, lack of randomized trials, and uncertainty in terms of doses and drugs are still challenges.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
F. F. Pepe, M. E. Cazzaniga, S. Baroni, F. Riva, F. Cicchiello, S. Capici, V Cogliati, C. Maggioni, N. Cordani, M. G. Cerrito, S. Malandrin
Summary: Different drug administration schedules can enhance anticancer immunity by regulating Treg cells. In a study involving 13 metastatic breast cancer patients, it was found that Treg numbers and function did not significantly change during the treatment, but there was a transient decrease in Treg numbers in some patients during the first 14 days. Additionally, memory Treg decreased while naive and activated Treg increased.
Article
Oncology
Lanqi Ren, Ning Ren, Yu Zheng, Yibei Yang, Qiaoping Xu
Summary: This study analyzed the cost-effectiveness of neratinib plus capecitabine (N+C) and lapatinib plus capecitabine (L+C) in HER2-positive metastatic breast cancer. The results showed that N+C was dominant in most scenarios, providing an improvement of 0.17 quality-adjusted life-years (QALYs) and reducing costs compared to L+C. The ICER was below the willingness to pay threshold, indicating that N+C is a cost-effective third-line treatment option for HER2-positive metastatic breast cancer patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Elisabetta Munzone, Meredith M. Regan, Saverio Cinieri, Emilia Montagna, Laura Orlando, Ruichao Shi, Enrico Campadelli, Lorenzo Gianni, Michela Palleschi, Fausto Petrelli, Carmelo Bengala, Daniele Generali, Elena Collova, Fabio Puglisi, Elisabetta Cretella, Claudio Zamagni, Claudio Chini, Barbara Ruepp, Sherene Loi, Marco Colleoni
Summary: This randomized clinical trial showed that oral vinorelbine plus cyclophosphamide plus capecitabine (VEX) significantly prolonged time to treatment failure (TTF) and progression-free survival (PFS) compared with intravenous paclitaxel in patients with estrogen receptor (ER)-positive, erb-b2 receptor tyrosine kinase 2 (ERBB2 [formerly HER2/neu])-negative (ER+/ERBB2-) metastatic breast cancer (MBC), but did not improve overall survival (OS).
Article
Oncology
Yue Chai, Jiaxuan Liu, Mingxia Jiang, Maiyue He, Zijing Wang, Fei Ma, Jiayu Wang, Peng Yuan, Yang Luo, Binghe Xu, Qiao Li
Summary: This single-arm prospective phase II trial assessed the efficacy and safety of dual oral metronomic vinorelbine and capecitabine (mNC) regimen in HER2-negative metastatic breast cancer patients in China. The results showed that the mNC regimen demonstrated very good safety features and improved compliance in both first- and second-line treatments, and achieved an excellent objective response rate (ORR) in the metastatic triple-negative breast cancer (mTNBC) subgroup.
Review
Oncology
Slavomir Krajnak, Marco J. Battista, Annette Hasenburg, Marcus Schmidt
Summary: Metronomic chemotherapy (MCT) is a continuous low-dose drug administration therapy that exerts its effects through immunomodulation, anti-angiogenesis, and direct cytotoxic effects. MCT can be considered as a safe and easy treatment option for selected MBC patients.
ONCOLOGY RESEARCH AND TREATMENT
(2022)
Article
Oncology
Longjiang She, Kun Tian, Jiaqi Han, Weihan Zuo, Zhu Wang, Ning Zhang
Summary: Adding metronomic capecitabine to concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma patients has been shown to be a cost-effective strategy, resulting in additional quality-adjusted life years and a favorable incremental cost-effective ratio at a willingness-to-pay threshold of $33,585 per QALY.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ji Hyung Hong, In Sook Woo
Summary: The use of immune checkpoint inhibitors (ICIs) in clinical practice for the treatment of metastatic colorectal cancer (mCRC) is currently limited to a small subset of patients. Combining ICIs with anti-angiogenic inhibitors has shown promising efficacy in early phase trials. Additionally, low-dose metronomic (LDM) chemotherapy has potential as a combination partner with ICIs for immunologically cold mCRC tumors.
Article
Oncology
E. Cazzaniga, I Vallini, E. Montagna, D. Amoroso, R. Berardi, A. Butera, K. Cagossi, L. Cavanna, M. Ciccarese, S. Cinieri, E. Cretella, E. De Conciliis, A. Febbraro, F. Ferrau, A. Ferzi, A. Baldelli, A. Fontana, A. R. Gambaro, O. Garrone, V Gebbia, D. Generali, L. Gianni, F. Giovanardi, A. Grassadonia, V Leonardi, P. Marchetti, S. Sarti, A. Musolino, M. Nicolini, C. Putzu, F. Riccardi, D. Santini, S. Saracchini, M. G. Sarobba, M. G. Schintu, G. Scognamiglio, P. Spadaro, C. Taverniti, D. Toniolo, P. Tralongo, A. Turletti, R. Valenza, M. R. Valerio, P. Vici, P. Di Mauro, V Cogliati, S. Capici, L. Clivio, V Torri
Summary: This study aimed to investigate the clinical activity of metronomic chemotherapy in triple-negative breast cancer patients. The overall response rate was 17.5%, with vinorelbine-based regimens being the most widely used.Median progression free survival was 6.0 months and overall survival was 12.1 months, showing potential benefits of mCHT in this poor prognosis subpopulation.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Emilia Montagna, Eleonora Pagan, Giuseppe Cancello, Claudia Sangalli, Vincenzo Bagnardi, Elisabetta Munzone, Emanuela Omodeo Sale, Daniela Malengo, Marina Elena Cazzaniga, Mara Negri, Giulia Peruzzotti, Paolo Veronesi, Giuseppe Viale, Marco Colleoni
Summary: Metronomic chemotherapy is an effective treatment option for metastatic breast cancer patients who require prolonged disease control without cumulative toxicity. In this study, the VEX regimen was found to induce prolonged clinical benefit in MBC patients with minimal side effects.
Article
Oncology
Vikas Garg, Lalit Kumar
Summary: Translational research and targeted therapies have significantly impacted the treatment of epithelial ovarian cancer. Recurrent ovarian cancer remains a challenge and requires innovative strategies. Metronomic chemotherapy, which inhibits angiogenesis and activates the immune system, has emerged as a promising approach.
Article
Oncology
Kerstin Wimmer, Monika Sachet, Cristiano Ramos, Sophie Frantal, Hanna Birnleitner, Christine Brostjan, Ruth Exner, Martin Filipits, Zsuzsanna Bago-Horvath, Margaretha Rudas, Rupert Bartsch, Michael Gnant, Christian F. Singer, Marija Balic, Daniel Egle, Rudolf Oehler, Florian Fitzal
Summary: This study compared the immunomodulatory effects of Epirubicin/cyclophosphamide (EC) and docetaxel (D) in neoadjuvant treatment of breast cancer. The results showed that EC had strong immunosuppressive properties, while D had a supportive effect on the immune system. These findings have important implications for the planning of combination therapies with immunotherapies in breast cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2023)
Article
Otorhinolaryngology
Chih-Wen Twu, Po-Ju Lin, Hsiao-Hui Tsou, Yi-Chun Liu, Rong-San Jiang, Kai-Li Liang, Tian-Yun Lin, Wen-Yi Wang, Jin-Ching Lin
Summary: This study investigated the survival impact and toxicity of maintenance metronomic chemotherapy in patients with metastatic/recurrent nasopharyngeal carcinoma. The results showed that maintenance chemotherapy significantly improved overall and progression-free survivals while demonstrating low toxicity.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Article
Oncology
David B. Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L. Redmond, Maritza Martel, Zhaoyu Sun, Mary B. Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S. Seitz, Tyler J. Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J. Urba, Heather L. McArthur
Summary: Chemoimmunotherapy with anti-PD-1/L1 and cytotoxic chemotherapy is a promising treatment for triple-negative breast cancer, but further research is needed to determine the optimal chemotherapy regimen and biomarkers for patient selection. This study investigated the safety and efficacy of pembrolizumab in combination with paclitaxel or capecitabine, and found that both regimens were safe and clinically active.
Article
Oncology
Stacey A. Santi, Margaret L. Meigs, Yantao Zhao, Mary A. Bewick, Robert M. Lafrenie, Michael S. Conlon
CANCER CAUSES & CONTROL
(2015)
Article
Multidisciplinary Sciences
Carly A. Buckner, Alison L. Buckner, Stan A. Koren, Michael A. Persinger, Robert M. Lafrenie
Article
Biology
Carly A. Buckner, Alison L. Buckner, Stan A. Koren, Michael A. Persinger, Robert M. Lafrenie
BIOELECTROMAGNETICS
(2017)
Letter
Environmental Sciences
Julie Burtt, Patsy Thompson, Robert Lafrenie
JOURNAL OF RADIOLOGICAL PROTECTION
(2016)
Review
Environmental Sciences
Julie J. Burtt, Patsy A. Thompson, Robert M. Lafrenie
JOURNAL OF RADIOLOGICAL PROTECTION
(2016)
Article
Oncology
C. A. Buckner, R. M. Lafrenie, J. A. Denommee, R. J. M. Caswell, D. A. Want
Article
Biology
Noa Gang, Glenn H. Parker, Robert M. Lafrenie, Michael A. Persinger
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2013)
Article
Multidisciplinary Sciences
Blake T. Dotta, Nirosha J. Murugan, Lukasz M. Karbowski, Robert M. Lafrenie, Michael A. Persinger
NATURWISSENSCHAFTEN
(2014)
Article
Oncology
Robert M. Lafrenie, Lisa Speigl, Carly A. Buckner, Graham Pawelec, Michael S. Conlon, Christopher Shipp
CLINICAL BREAST CANCER
(2019)
Article
Biochemistry & Molecular Biology
Ali Zari, Hajer Alfarteesh, Carly Buckner, Robert Lafrenie
Summary: Uncaria tomentosa demonstrated potent anti-cancer activity both in vitro and in vivo, particularly with its ethanolic extracts; it reduced tumor size and weight, decreased the proliferation marker Ki-67, inhibited angiogenic markers, and reduced T-cell infiltration into tumors.
Article
Multidisciplinary Sciences
Alison L. Buckner, Carly A. Buckner, Sabine Montaut, Robert M. Lafrenie
Article
Pharmacology & Pharmacy
Lisa Allen, Alison Buckner, Carly A. Buckner, Pablo Cano, Robert M. Lafrenie
PHARMACOGNOSY RESEARCH
(2017)
Article
Multidisciplinary Sciences
Nya L. Fraleigh, Justin Boudreau, Nitin Bhardwaj, Nelson F. Eng, Yanal Murad, Robert Lafrenie, Reinaldo Acevedo, Reynaldo Oliva, Francisco Diaz-Mitoma, Hoang-Thanh Le
Article
Biochemistry & Molecular Biology
Blake T. Dotta, Robert M. Lafrenie, Lukasz M. Karbowski, Michael A. Persinger
GENERAL PHYSIOLOGY AND BIOPHYSICS
(2014)
Article
Biology
Carly A. Buckner, Alison L. Buckner, Stan A. Koren, Michael A. Persinger, Robert M. Lafrenie
BIOELECTROMAGNETICS
(2018)